DrugPatentWatch Database Preview

Pfizer Company Profile

PFIZER has one hundred and thirty-seven approved drugs.

There are thirty-eight US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.

There are seven hundred and fifty-seven patent family members on PFIZER drugs in sixty-seven countries and one hundred and sixty supplementary protection certificates in nineteen countries.

International Patents:	757
US Patents:	38
Tradenames:	108
Ingredients:	96
NDAs:	137
Drug Master File Entries:	3
Patent Litigation for Pfizer:	See patent lawsuits for Pfizer
PTAB Cases with Pfizer as petitioner:	See PTAB cases with Pfizer as petitioner

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651-001	Oct 16, 2018		RX	Yes	No	8,012,976	Start Trial	Y	Y		Start Trial
Pfizer	TERRAMYCIN-POLYMYXIN	oxytetracycline hydrochloride; polymyxin b sulfate	TABLET;VAGINAL	061009-001	Approved Prior to Jan 1, 1982		DISCN	No	No		Start Trial				Start Trial
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868-002	Nov 2, 2018		RX	Yes	Yes		Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	COVERA-HS	verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020552-002	Feb 26, 1996	6,146,662	Start Trial
Pfizer	MINIZIDE	polythiazide; prazosin hydrochloride	CAPSULE;ORAL	017986-002	Approved Prior to Jan 1, 1982	3,663,706	Start Trial
Pfizer	DIFLUCAN	fluconazole	TABLET;ORAL	019949-004	Jun 30, 1994	4,416,682	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	82.5 mg and 165 mg	➤ Subscribe	2018-02-02
➤ Subscribe	Extended-release Tablets	82.5 mg and 165 mg	➤ Subscribe	2018-02-02
➤ Subscribe	Extended-release Tablets	11 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Capsules	20 mg, 40 mg, 60 mg and 80 mg	➤ Subscribe	2005-02-07
➤ Subscribe	Capsules	25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg	➤ Subscribe	2008-12-30
➤ Subscribe	Capsules	5 mg and 10 mg	➤ Subscribe	2005-06-21
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2011-06-17
➤ Subscribe	Delayed-release Tablets	75 mg/0.2 mg	➤ Subscribe	2008-11-28
➤ Subscribe	Extended-release Tablets	330 mg	➤ Subscribe	2018-01-29
➤ Subscribe	Extended-release Tablets	330 mg	➤ Subscribe	2018-01-29
➤ Subscribe	Extended-release Tablets	4 mg and 8 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Injection	20 mg/mL, 2 mL and 5 mL vials	➤ Subscribe	2004-07-26
➤ Subscribe	Capsules	75 mg, 100 mg and 125 mg	➤ Subscribe	2019-02-04
➤ Subscribe	Oral Solution	20 mg/mL	➤ Subscribe	2010-05-19
➤ Subscribe	Capsules	0.125 mg, 0.25 mg, and 0.5 mg	➤ Subscribe	2014-05-01
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Delayed-release Tablets	50 mg/0.2 mg	➤ Subscribe	2009-06-29

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2822953	2019C/539	Belgium	Start Trial	PRODUCT NAME: LORLATINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1355 20190508
1470124	122017000014	Germany	Start Trial	PRODUCT NAME: PALBOCICLIB, OPTIONAL IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, ESTERS, AMIDES ODER EINES PRODRUGS HIERVON; REGISTRATION NO/DATE: EU/1/16/1147 20161109
1235830	C01235830/01	Switzerland	Start Trial	PRODUCT NAME: TOFACITINIB; REGISTRATION NO/DATE: SWISSMEDIC 62630 12.07.2013
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.